Trials
25 active
56 in total · 45 in the EU
What this is
- How it works
- Makes the kidneys flush extra sugar and salt into the urine. Started as a diabetes drug; now also used for heart and kidney disease.Sodium-Glucose Cotransporter 2 Inhibitor FDA class
- Tested for
- Heart Failure (2 trials), Kidney Disease, Chronic, Chronic Kidney Disease, Diabetes Mellitus, Type 2, Hypertension, Cardiovascular Diseases
- Main trialPhase 3
- “This study is open to adults with chronic kidney disease at risk of progression. People with and without type 2 diabetes can take part in this study. The study is open to people who take other medicines called angiotensin converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB). People who already take empagliflozin or any other sodium-glucose cotransporter-2 inhibitor (SGLT2i) can also join. The study is also open to people who currently do not take any of these treatments. The purpose of this study is to find out whether a medicine called BI 690517 helps people with…”In the company’s words, NCT06531824 on ClinicalTrials.gov
- Other names
- Jardiance · JARDIANZ · GIBTULIO
Other drugs for Heart Failure
- Balcinrenone/ dapagliflozinAstraZeneca · Phase 3
- DapagliflozinAstraZeneca · Phase 3
- HiCM-188HELP Therapeutics Co., Ltd. · Phase 3
- Omecamtiv MecarbilCytokinetics · Phase 3
- InclisiranNovartis Pharmaceuticals · Phase 3
- VicadrostatBoehringer Ingelheim · Phase 3
Copies tested against it4
Other companies’ versions, mostly cheaper copies for when the patent ends
- Empagliflozin film coatedHumanis Saglık Anonim Sirketi · NCT06180109 · finished
- Linagliptin film-coatedHumanis Saglık Anonim Sirketi · NCT06932159, NCT07039890 · finished
- Empagliflozin / Metformin Extended-ReleaseHumanis Saglık Anonim Sirketi · NCT07694115 · finished
- Emapgliflozin/MetforminHumanis Saglık Anonim Sirketi · NCT06450262 · finished
Coming up6
- 11 DecPhase 1 trial completes · ClinicalTrials.gov
- 31 DecPhase 3 trial completes · ClinicalTrials.gov
- 16 Apr 2027Phase 3 trial completes · ClinicalTrials.gov
- 22 May 2028Phase 3 trial completes · ClinicalTrials.gov
- 4 Feb 2029Phase 3 trial completes · ClinicalTrials.gov
- 14 Dec 2029Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials56
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 31 Dec 2026 | EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin) | |
| Phase 3Active, not recruiting | 16 Apr 2027 | A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids) | |
| Phase 3Recruiting | 22 May 2028 | A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure | |
| Phase 3Recruiting | 4 Feb 2029 | A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart | |
| Phase 3Recruiting | 14 Dec 2029 | EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease | |
| Phase 1Recruiting | 11 Dec 2026 | A Study in Healthy People to Compare How 2 Different Formulations of Vicadrostat / Empagliflozin Tablets Are Taken up in the Body | |
| Phase 4Completed | 19 Aug 2022 | A Study to Test How Well Empagliflozin Works in Japanese People With Type 2 Diabetes Who Are Older Than 65 Years | |
| Phase 3Completed | 1 May 2020 | EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced) | |
| Phase 3Completed | 21 May 2020 | A Study That Looks at the Function of the Heart in Patients With Heart Failure Who Take Empagliflozin | |
| Phase 3Completed | 26 Apr 2021 | EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved) | |
| Phase 3Completed | 28 May 2021 | A Study to Test the Effect of Empagliflozin in Patients Who Are in Hospital for Acute Heart Failure | |
| Phase 3Completed | 3 Mar 2022 | A Study to Test How Well Empagliflozin Works in Chinese Patients With Type 2 Diabetes Who Already Take Insulin | |
| Phase 3Completed | 5 Jul 2022 | EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin) | |
| Phase 3Completed | 19 Oct 2022 | Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM | |
| Phase 3Completed | 5 Nov 2023 | EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction) | |
| Phase 2Completed | 19 Jun 2023 | A Study to Test Whether Different Doses of BI 690517 Alone or in Combination With Empagliflozin Improve Kidney Function in People With Chronic Kidney Disease | |
| Phase 2Terminated | 23 Apr 2024 | A Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin Helps People With Liver Cirrhosis Caused by Viral Hepatitis or Non-alcoholic Steatohepatitis (NASH) Who Have High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver) | |
| Phase 2Completed | 14 Aug 2026 | A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease | |
| Phase 1Completed | 6 Aug 2021 | A Study in Healthy Humans to Assess the Relative Bioavailability of One Fixed-dose Combination Tablet Empagliflozin/Metformin Versus Jardiance® Tablet and Glifage® Tablet Administered Together | |
| Phase 1Completed | 26 Jun 2025 | A Study in Healthy People to Test How Empagliflozin is Taken up in the Body When Taken as a Whole Tablet or Dissolved in Water and Mixed With Food | |
| Phase 1Completed | 7 Aug 2025 | A Study in Healthy Men to Compare the Amount of Vicadrostat and Empagliflozin in the Blood When Taken Separately and Together | |
| Phase 1Completed | 22 Oct 2025 | A Study in Healthy People to Test How 2 Different Formulations of a Combination Treatment (Vicadrostat and Empagliflozin) Are Taken up in the Body and How Food Influences the Amount of the Medicines in the Blood | |
| Phase 4Ended | not given | The effect of empagliflozin on peripheral microvascular dysfunction in heart failure with preserved ejection fraction | |
| Phase 3/4Ended | not given | Initiation of angiotensin receptor-neprilysin inhibitor (ARNi) and sodium-glucose cotransporter-2 inhibitors (SGLT2i) in patients with heart failure with reduced ejection fraction (HFrEF): the INITIATE-HFrEF randomized open-label trial | |
| Phase 3Authorised | not given | Effect at 3 months of early empagliflozin initiation in cardiogenic shock patients on mortality, rehospitalization, left ventricular ejection fraction and renal function. A randomized multicentric open trial. (EMPASHOCK) | |
| Phase 2Ended | not given | Effects of empagliflozin on plasma glucose in patients with HNF1A-MODY: a randomized, double-blind, crossover trial | |
| Phase 4Ended | not given | EMPagliflozin after Aortic Valve Replacement - the EMPAVR study - a randomized clinical trial | |
| Phase 4Authorised | not given | Study of Empagliflozin in Patients with Autosomal Dominant Polycystic Kidney Disease | |
| Phase 1Ended | not given | Comparative Bioavailability of Empagliflozin 25 mg Film-Coated Tablets: A Single-Dose, Open-Label, Randomized, Two-Sequence, Two-Treatment, Two-Period Crossover Study in Healthy Subjects Under Fasting Conditions. | |
| Phase 4Ended | not given | Optimization of Albuminuria-Lowering Therapies for Individual Patients with Type 2 Diabetes Using Empagliflozin and Finerenone in a Pilot Remote Clinical Trial | |
| Phase 2Ended | not given | Effect of the SGLT2 inhibitor empagliflozin in patients with euvolemic and hypervolemic hyponatremia – a multicentric randomized double-blind placebo-controlled trial (the EMPOWER Study) | |
| Phase 3Authorised | not given | COmbiNed eFfIcacy and safety of an eaRly, intensive MAnagement sTrategy with fInerenOne and SGLT2 iNhibitor in patients hospitalized with Heart Failure (CONFIRMATION-HF) | |
| Phase 3Authorised | not given | BIOmarker driven intensification of cardiovascular RISK factor management in patients with high risk for recurrent cardiovascular EVENTs | |
| Phase 2Ended | not given | The impact of Empagliflozin on Left atrIal Volume and the feasibility of using Fitbit and mHealth to prescribe Exercise in non-diabetic Pre- Heart Failure (ELIVE pre-HF Study) | |
| Phase 2Ended | not given | Evaluation of the efficacy and safety of empagliflozin in the treatment of neutropenia in patients with glycogenosis Ib. EMPAtia. | |
| Phase 2Authorised | not given | Adipose Tissue Heterogeneity and Its Link to Type 2 Diabetes: A Randomized Open Intervention Study That Compares Empagliflozin, Pioglitazone and Semaglutide (DiaSpax) | |
| Phase 2Ended | not given | Acute effects of SGLT2 inhibitor on kidney allograft oxygen tension: A randomized, double-blind, placebo controlled crossover trial | |
| Phase 4Authorised | not given | Acetazolamide in combination with SGLT2i in patients with volume overload and acute heart failure | |
| Phase 3Authorised | not given | A Phase 3, Randomized, Double-blind, Placebo-controlled Study to evaluate Efficacy and Safety of Empagliflozin in the prevention of Cardiotoxicity in Cancer patients undergoing Chemotherapy based on Anthracyclines (EMPACT study) | |
| Phase 2Halted | not given | Proof-of-concept study of Empagliflozin in patients with pulmonary arterial hypertension (EmPAH) | |
| Phase 3Ended | not given | The use of empagliflozin in patients with hypertrophic cardiomyopathy | |
| Phase 3Authorised | not given | Effects of continued administration of empagliflozin in patients with heart failure on active SGLT2 inhibitor treatment admitted for acute decompensated heart failure | |
| Phase 4Authorised | not given | Reducing Non-Alcoholic Steatohepatitis | |
| Phase 3Authorised | not given | EMpagliflozin and daPAgliflozin in patients hospiTalized for acute decompensated Heart failure (EMPATHY) – a phase III Trial | |
| Phase 4Ended | not given | Intraclass safety and efficacy comparison among SGLT-2 inhibitors in elderly patients with type 2 diabetes. A pragmatic, phase IV, multicenter, open-label, randomised controlled trial. | |
| Phase 3Authorised | not given | Prevention of cardiac surgery-associated acute kidney injury through the use of sodium-glucose cotransporter 2 inhibitors | |
| Phase 4Authorised | not given | Pharmacological optimization in prevention in Heart Failure: A Sex-gap? (PopS-HF Trial) | |
| Phase 4Ended | not given | Open-label, double-arm, controlled, randomized, multicentre clinical trial to evaluate the impact of pharmacogenetic-guided treatment in patients with insufficiently controlled type 2 diabetes | |
| Phase 4Ended | not given | SGLT-2i, Heart, Improvement of Cardiovascular Autonomic Neuropathy | |
| Phase 3/4Authorised | not given | Withdrawal of neurohormonal therapy in patients with non-ischemic cardiomyopathy, no late gadolinium enhancement, and negative genetic testing, who have exhibited super-response to cardiac resynchronization therapy. DRUGLESS-CRT clinical trial. | |
| Phase 3Authorised | not given | Effect of Empagliflozin in patients with eGFR between 10 and 20 ml/min/1.73m2 - EMPA [10-20] | |
| Phase 4Authorised | not given | A prospective, randomized, controlled clinical pilot trial investigating the partial down-titration of guideline-directed medical therapy in patients with heart failure in remission | |
| Phase 3Authorised | not given | Sodium-glucose cotransporter-2 inhibitors to stABiLizE coronary atherosclerosis pro-gression after acute Myocardial Infarction in women and men with diabetes mellitus | |
| Phase 4Authorised | not given | Discontinuation or Continuation of SGLT-2 Inhibitors Before Cardiac Surgery: Impact on Postoperative Cardiovascular Outcomes – DISCO Study | |
| Phase 3Authorised | not given | A phase III, randomized, prospective, double-blind, parallel design, multi-arm, multicenter study to compare the efficacy and safety of alogliptin and empagliflozin combination therapy versus alogliptin alone and empagliflozin alone in metformin-treated participants with type 2 diabetes mellitus and insufficient glycemic control despite diet and exercise (ODISSEIA 2026). | |
| Phase 2/3Authorised | not given | The GranStone Trial - Prevention of Kidney Stones due to Paraffin Oil Induced Granuloma |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026